DevvStream

BIORA THERAPEUTICS (NASDAQ: BIOR) STOCK QUOTE

Last Trade: US$0.66 -0.04 -5.89
Volume: 201,962
5-Day Change: -0.54%
YTD Change: -51.11%
Market Cap: US$23.680M

LATEST NEWS FROM BIORA THERAPEUTICS

Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, presented supplemental... Read More
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of Medicine at Mount Sinai) and Brian Feagan, MD, FRCPC (Schulich School of Medicine & Dentistry at the University of Western Ontario),... Read More
Drug-device combination leverages Biora’s NaviCap™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ability to deliver therapeutics directly to the colon Drug absorption in colonic tissue extended to distal colon, suggesting pan-colonic delivery Company to host virtual event... Read More
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit, which will take place June 18–20, 2024 in Boston. Details of the presentation are as follows: Presentation Title:... Read More
SAN DIEGO, May 20, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, presented a poster titled “Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC” at the Digestive Disease Week® conference in Washington DC, on Sunday, May 19, 2024. “In four separate clinical studies,... Read More
Dosing of all patients in clinical trial of BT-600 has been successfully completed, with results anticipated in late Q2 2024 Clinical data on device function of the NaviCap™ platform to be presented at DDW on May 19 Partnering process for the BioJet oral delivery platform is progressing well Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) --... Read More
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the first quarter ended March 31, 2024. The company’s management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets. Conference Call and... Read More
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data on device function of the NaviCap™ Targeted Oral Delivery Platform at Digestive Disease Week ® (DDW), which will take place both virtually and in-person May 18-21, 2024 in Washington, DC. Details of the presentations are as... Read More
Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late Q2 2024 SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced completion of dosing for the multiple-ascending dose cohorts for its clinical study of BT-600, a drug-device combination consisting of... Read More
SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The United States... Read More
GreenStockNews
All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap™ devices performed as intended and were well tolerated, with no safety signals observed Multiple-ascending dose (MAD) portion of the trial is underway and progressing well SAN DIEGO, April 04,... Read More
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously announced registered direct offering of an aggregate of 5,454,548 shares of the Company’s common stock at an offering price of $1.10 per share of common stock and concurrent private placement of unregistered warrants to purchase up... Read More
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 5,454,548 shares of the Company’s common stock at an offering price of $1.10 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In... Read More
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood Remainder of BT-600 clinical trial progressing well and on schedule Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, March 26, 2024 (GLOBE NEWSWIRE) -- Biora... Read More
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the fourth quarter and full year ended December 31, 2023. The company’s management will host a webcast and conference call on Tuesday, March 26, 2024, after the close of financial markets.... Read More
Monetization of legacy asset brings in $3 million in nondilutive capital Convertible notes exchange brings in another $2.8 million in new capital and reduces Biora’s net debt SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced an agreement with institutional investor Context Capital to invest $2.8 million in new... Read More
Data expected to be shared during March corporate update With SAD cohorts complete, MAD cohorts to begin dosing in March SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced completion of the single-ascending dose (SAD) cohorts for its phase 1, first-in-human clinical study of BT-600 in healthy adult volunteers.... Read More
SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will participate in the Inflammatory Bowel Disease Symposium hosted virtually by Canaccord Genuity Capital Markets on Wednesday, February 28, 2024. Ariella Kelman, M.D., Chief Medical Officer, will participate in the panel titled “ The Next Evolutionary Steps... Read More
SAN DIEGO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced participation in a virtual fireside chat hosted by H.C. Wainwright & Co. on Monday, January 29, 2024 at 11:00 AM Eastern / 8:00 AM Pacific. Adi Mohanty, CEO, Ariella Kelman, M.D., CMO, and Eric d’Esparbes, CFO, will discuss the company’s delivery platforms... Read More
SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided guidance on anticipated milestones during 2024. “In 2023, we completed the transformation of the company, focusing on strong execution which laid the foundation for significant value inflection in the coming months,” said Adi Mohanty, Chief Executive Officer of... Read More
First-in-human trial of BT-600 drug-device combination, following multiple successful device-only human studies SAD/MAD study to evaluate safety and PK/PD of BT-600, including concentrations in colon tissue SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced initiation of its phase 1, first-in-human clinical study... Read More
SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that its BioJet™ Systemic Oral Delivery Platform has met key performance milestones as part of its research collaboration with AstraZeneca. The BioJet platform is designed to use needle-free, liquid jet injection to deliver drug into the small intestine for... Read More
SAN DIEGO, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it received an Issue Notification from the U.S. Patent and Trademark Office for a patent related to the treatment of gastrointestinal (GI) disorders through targeted delivery of JAK inhibitors for its NaviCap™ targeted oral delivery platform under... Read More
Transaction results in nearly 60% reduction in net debt and brings $16.7 million in new capital for the company Demonstrates investor confidence in near-term catalysts for NaviCap™ and BioJet™ platforms SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced an agreement with institutional investors Athyrium Capital... Read More
SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced a new research collaboration with a large pharmaceutical company for its BioJet™ Systemic Oral Delivery Platform. The new agreement provides funding to test the BioJet platform’s ability to achieve bioavailability through oral delivery of the undisclosed... Read More
BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for BT-600, a... Read More
NaviCap™ Targeted Oral Delivery platform advancing toward initiation of phase 1 clinical trial by year end Pharma collaborations accelerate for the BioJet™ Systemic Oral Delivery platform, which shows potential for liver-targeted delivery of large molecules Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq:... Read More
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2023. The company’s management will host a webcast and conference call on Monday, November 13, 2023, after the close of financial markets at 4:30 PM Eastern... Read More
Update includes supplemental information and provides additional time to complete regulatory review Biora anticipates remaining on track with its phase 1 clinical trial execution timeline SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it submitted an updated Investigational New Drug (IND) application for... Read More
Biora anticipates remaining on track with its phase 1 clinical trial execution timeline Update to include supplemental information and allow additional time to complete regulatory review SAN DIEGO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced an update regarding its Investigational New Drug (IND) application. The IND... Read More
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, presented data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion titled “Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 Receptor Agonist Delivered through the BioJet™ Biotherapeutic Delivery... Read More
BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis IND application is supported by robust clinical device function data SAN DIEGO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced submission of an Investigational New Drug... Read More
Funds managed by Athyrium Capital Management increase their equity exposure through a convertible notes exchange at a price representing a 44% premium to the closing price on September 18, 2023 Transaction results in a debt reduction of $50 million for the company On track to file an IND this month for NaviCap™ BT-600 targeted oral delivery program SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc.... Read More
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will present at the upcoming H.C. Wainwright 25 th Annual Global Investment Conference being held September 11-13, 2023 in New York City. The Biora presentation will begin on Wednesday, September 13, at 11:00 AM Eastern time. Biora management will also... Read More
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced achievement of its device performance targets for the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The company... Read More
NaviCap™ targeted oral delivery platform on track for September IND filing; achieved successful device function study results in humans with phase 1-ready device BioJet™ systemic oral delivery platform device development achieved function targets while continuing to exceed bioavailability targets The company strengthened its intellectual property position with additional patents for both platforms Management will host... Read More
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent and the allowance of a patent application related to the company’s BioJet™ platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the... Read More
SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that management will be attending the Canaccord Genuity 43 rd Annual Growth Conference in Boston. On Thursday, August 10, Eric d’Esparbes, Chief Financial Officer, will participate in a fireside chat. Mr. d’Esparbes will answer questions about the company... Read More
SAN DIEGO, July 27, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced progress with its latest clinical device performance study, evaluating the device function and safety of its NaviCap™ targeted oral delivery platform. “In this study evaluating twelve subjects to date, the NaviCap device accurately identified entry into the... Read More
SAN DIEGO, July 17, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report financial results and provide a corporate update for the second quarter ended June 30, 2023. The company’s management will host a webcast and conference call on Monday, August 14, 2023, after the close of financial markets at 4:30 PM Eastern... Read More
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has completed an agreement with a large diagnostics company for the sale of legacy assets related to Biora’s former diagnostics business. “This represents continued progress in monetizing our legacy assets,” said Eric d’Esparbes, Chief Financial Officer... Read More
SAN DIEGO, June 28, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap™ targeted oral delivery platform under development. The patents are directed to methods of treating ulcerative colitis using an... Read More
SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today shared detailed results from its preclinical study titled “Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 (GLP-1) Receptor Agonist delivered through the BioJet™ Oral Biotherapeutic Delivery Platform in a Porcine Model,” which were presented during the... Read More
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced the closing of its previously announced registered direct offering of an aggregate of 1,509,434 shares of the Company’s common stock at an offering price of $5.30 per share of common stock and concurrent private placement of warrants to... Read More
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced that it has entered into a definitive agreement for the purchase and sale of 1,509,434 shares of the Company’s common stock at an offering price of $5.30 per share of common stock in a registered direct offering priced at-the-market... Read More
SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion at the 59 th annual meeting of the European Association for the Study of Diabetes, to be held October... Read More
Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in preliminary data; on track to file IND in Q3 2023 Preclinical testing for the BioJet™ platform is advancing both internally and with pharma collaborator’s molecule Data from preclinical study of the BioJet platform with GLP-1 receptor agonist was accepted as a late-breaking abstract for presentation at upcoming scientific... Read More
SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report first quarter ended March 31, 2023 financial results on Monday, May 15, 2023 after the close of financial markets. The company’s management will host a webcast and conference call at 4:30 PM Eastern time / 1:30 PM Pacific time that day to... Read More
SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelman has a proven track record of leading global biopharmaceutical development, clinical trials, and regulatory strategies. “Dr. Kelman is an outstanding addition to our team as we progress our... Read More
SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will participate in IBD Innovate: Product Development for Crohn’s & Colitis , an event hosted by the Crohn’s & Colitis Foundation to showcase innovative product development programs in inflammatory bowel disease (IBD), which will take place in New York... Read More
Biora initiating preclinical testing with pharma collaborator’s molecule following recent data exceeding the company’s target bioavailability levels for systemic therapeutics platform No adverse events indicated in 14-day tox study for targeted therapeutics program Announcing new brand names for Biora’s therapeutics platforms: the NaviCap™ targeted oral delivery platform and the BioJet™ systemic oral delivery platform... Read More
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report fourth quarter and full year ended December 31, 2022 financial results on Thursday, March 30, 2023 after the close of financial markets. The company’s management will host a webcast and conference call at 4:30 PM Eastern time / 1:30 PM... Read More
SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced preliminary results from preclinical testing of its PGN-OB2 program, reporting an average bioavailability of 37% for semaglutide, a GLP-1 receptor agonist. Semaglutide is currently marketed as two subcutaneously administered formulations under the brand names... Read More
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced preliminary results from preclinical testing of its PGN-OB1 program, reporting an average bioavailability greater than 50% for a variant of adalimumab. “In this preclinical study, we assessed the bioavailability of a variant of adalimumab when delivered via our... Read More
SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today presented detailed results from its PM-611 study titled “Potential effects of food on a novel Drug Delivery System (DDS) to deliver therapeutic compound into the colon” during the Crohn’s & Colitis Congress in Denver, CO, being held January 19-21, 2023. “In this study, we... Read More
SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced feedback from the United States Food and Drug Administration (FDA) on its clinical development plans for its PGN-600 program, and provided program updates. For Biora’s Targeted Therapeutics Platform, which is focused on treatment of ulcerative colitis (UC), the... Read More
SAN DIEGO, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will effect a reverse stock split of all outstanding shares of the company’s common stock at a ratio of 25 to 1. The company expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Global Market as of the commencement of trading on... Read More
SAN DIEGO, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced acceptance of two abstracts presenting patient data on its targeted therapeutics delivery system for presentation at the Crohn’s & Colitis Congress, which will take place January 19-21, 2023, in Denver, Colorado. This annual conference, a partnership of the... Read More
SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it has completed an agreement to license its Preecludia™ rule-out test for preeclampsia to Avero Diagnostics, formerly Northwest Pathology, for commercial development. “We have been impressed with the Avero team’s execution on several diagnostic assets, and we... Read More
Presented results of human study at the American College of Gastroenterology annual meeting, demonstrating promising device performance in active ulcerative colitis patients Executed a registered direct capital raise of $9.75 million Presented preclinical results demonstrating the possibilities for systemic delivery of large molecules using the company's systemic delivery platform Received key patent for oral delivery of... Read More
SAN DIEGO, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report third quarter ended September 30, 2022 financial results on Monday, November 14, 2022 after the close of financial markets. The company’s management will host a webcast and conference call at 4:30 PM Eastern time / 1:30 PM Pacific time that... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into a definitive agreement with institutional investors for the purchase and sale, in a registered direct offering, of 32,506,250 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 32,506,250 shares of common stock at a combined... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it has completed a one-time asset sale agreement to assign certain patent rights related to methods for determining the origin of cell-free DNA to Roche Diagnostics. Financial terms were not disclosed. The patent rights being assigned, which resulted from the company’s previous molecular diagnostics... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today presented detailed results from its PM-602 study titled “A scintigraphic study to evaluate the localization and delivery function of a Drug Delivery System (DDS) device in patients with active ulcerative colitis (UC) in fasted state” during the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the five posters presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, which is being held in Charlotte, NC and virtually from October 21–26, 2022. At the ACG meeting, the company presented detailed results from two human trials for its targeted therapeutics platform... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared a poster presented at the Parenteral Drug Association (PDA) Universe of Pre-Filled Syringes and Injection Devices Conference. The meeting in Palm Springs, California, October 18-19, 2022 explored the latest technological advances with drug delivery devices. “Our platform is the first designed to use submucosal liquid... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today that the company will participate in the 12th annual Partnership Opportunities in Drug Delivery (PODD) Conference , October 24-25, 2022 in Boston. Chris Wahl, MD, MBA, Head of Strategy and Business Development at Biora Therapeutics, will participate in the panel titled "Discussing the Future of Oral Drug Delivery... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today that the United States Patent and Trademark Office (USPTO) has issued a patent related to the company’s technologies for oral, systemic delivery of biologics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The USPTO has issued U.S. Patent No.... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, announced today the appointment of Dr. Bruce Sands as board chair of its Clinical Advisory Board for Inflammatory Bowel Disease (IBD), which also includes leading IBD researchers Dr. Geert D’Haens, Dr. Brian Feagan, and Dr. Séverine Vermeire. The clinical advisory board provides strategic guidance on clinical development of... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company’s management team will be presenting and participating in one-on-one meetings at the H.C. Wainwright 24 th Annual Global Investment Conference, which is taking place both virtually and at the Lotte New York Palace Hotel in New York City, September 12-14, 2022. Investors who are interested in... Read More
Successfully completed PM-602 human study for its targeted therapeutics platform demonstrating promising device performance in active ulcerative colitis patients Successfully completed PM-611 human study for its targeted therapeutics platform in healthy volunteers showing promising performance regardless of feeding schedule Confirmed planned phase 1 IND filing in Q1 based on FDA feedback on PGN-600 program in ulcerative... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that it will report second quarter ended June 30, 2022 financial results on Monday, August 15, 2022 after the close of financial markets. The company’s management will host a webcast and conference call at 4:30 PM Eastern time / 1:30 PM Pacific time that day to discuss the financial results and provide a corporate... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced the acceptance of five abstracts for presentation at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting. ACG’s mission is to advance world-class care for patients with gastrointestinal disorders through excellence, innovation, and advocacy in the areas of scientific investigation,... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced that the company’s management team will be participating in one-on-one meetings at the upcoming BTIG Biotechnology Conference, which is taking place both virtually and at the St. Regis New York Hotel in New York City, August 8-9, 2022. For those interested in meeting with Biora at the conference, please reach out... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared two posters that were presented at the Controlled Release Society (CRS) 2022 Annual Meeting, which is being held July 11-15, 2022, in Montreal, Canada. CRS is an international gathering of experts in the design, development, and implementation of novel drug delivery technologies. “We are presenting results of early... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced topline results from its recently completed study PM-611: Safety and Functionality Assessment of the Drug Delivery System (DDS) Capsule in humans. The study assessed whether the autonomous location functionality of the ingestible devices was impacted by a fed state as compared to a fasted state. The study... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced the acceptance of an abstract presenting data on the autonomous triggering and injection efficiency of its systemic therapeutics delivery system by the Parenteral Drug Association (PDA) Universe of Pre-Filled Syringes and Injection Devices Conference . This meeting explores the latest technological advances in the... Read More
Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared a presentation delivered during Digestive Disease Week® (DDW), May 21-24, 2022 in San Diego. DDW is the world’s premier meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. Key opinion leader Dr. Séverine Vermiere gave a presentation... Read More
Patient Data Suggests Multiple Additional Inflammatory Pathways, Supporting Potential Need for Combination Therapy for Ulcerative Colitis Patient Data Establishes Proof of Concept for Microbiome Sampling Capsule Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared two posters that were presented during the Digestive Disease Week ® (DDW), May 21-24, 2022 in San Diego.... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS